129 related articles for article (PubMed ID: 11861369)
1. Trk receptor inhibition induces apoptosis of proliferating but not quiescent human osteoblasts.
Pinski J; Weeraratna A; Uzgare AR; Arnold JT; Denmeade SR; Isaacs JT
Cancer Res; 2002 Feb; 62(4):986-9. PubMed ID: 11861369
[TBL] [Abstract][Full Text] [Related]
2. Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells.
Weeraratna AT; Dalrymple SL; Lamb JC; Denmeade SR; Miknyoczki S; Dionne CA; Isaacs JT
Clin Cancer Res; 2001 Aug; 7(8):2237-45. PubMed ID: 11489797
[TBL] [Abstract][Full Text] [Related]
3. Anti-proliferative effect of the kinase inhibitor K252a on human prostatic carcinoma cell lines.
Delsite R; Djakiew D
J Androl; 1996; 17(5):481-90. PubMed ID: 8957691
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine kinase inhibitor CEP-701 blocks the NTRK1/NGF receptor and limits the invasive capability of prostate cancer cells in vitro.
Festuccia C; Muzi P; Gravina GL; Millimaggi D; Speca S; Dolo V; Ricevuto E; Vicentini C; Bologna M
Int J Oncol; 2007 Jan; 30(1):193-200. PubMed ID: 17143529
[TBL] [Abstract][Full Text] [Related]
5. Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587).
Dionne CA; Camoratto AM; Jani JP; Emerson E; Neff N; Vaught JL; Murakata C; Djakiew D; Lamb J; Bova S; George D; Isaacs JT
Clin Cancer Res; 1998 Aug; 4(8):1887-98. PubMed ID: 9717816
[TBL] [Abstract][Full Text] [Related]
6. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
George DJ; Dionne CA; Jani J; Angeles T; Murakata C; Lamb J; Isaacs JT
Cancer Res; 1999 May; 59(10):2395-401. PubMed ID: 10344749
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts.
Fizazi K; Yang J; Peleg S; Sikes CR; Kreimann EL; Daliani D; Olive M; Raymond KA; Janus TJ; Logothetis CJ; Karsenty G; Navone NM
Clin Cancer Res; 2003 Jul; 9(7):2587-97. PubMed ID: 12855635
[TBL] [Abstract][Full Text] [Related]
8. Mixed-lineage kinase inhibitors require the activation of Trk receptors to maintain long-term neuronal trophism and survival.
Wang LH; Paden AJ; Johnson EM
J Pharmacol Exp Ther; 2005 Mar; 312(3):1007-19. PubMed ID: 15525794
[TBL] [Abstract][Full Text] [Related]
9. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
10. Effect of exogenous neurotrophins on Trk receptor phosphorylation, cell proliferation, and neurotrophin secretion by cells isolated from the human lamina cribrosa.
Lambert WS; Clark AF; Wordinger RJ
Mol Vis; 2004 Apr; 10():289-96. PubMed ID: 15105791
[TBL] [Abstract][Full Text] [Related]
11. Nitroxide tempo, a small molecule, induces apoptosis in prostate carcinoma cells and suppresses tumor growth in athymic mice.
Suy S; Mitchell JB; Samuni A; Mueller S; Kasid U
Cancer; 2005 Mar; 103(6):1302-13. PubMed ID: 15685617
[TBL] [Abstract][Full Text] [Related]
12. The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma.
Miknyoczki SJ; Chang H; Klein-Szanto A; Dionne CA; Ruggeri BA
Clin Cancer Res; 1999 Aug; 5(8):2205-12. PubMed ID: 10473107
[TBL] [Abstract][Full Text] [Related]
13. Development and characterization of a conditionally immortalized human fetal osteoblastic cell line.
Harris SA; Enger RJ; Riggs BL; Spelsberg TC
J Bone Miner Res; 1995 Feb; 10(2):178-86. PubMed ID: 7754797
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo effects of bicalutamide on the expression of TrkA and P75 neurotrophin receptors in prostate carcinoma.
Festuccia C; Gravina GL; Muzi P; Pomante R; Ventura L; Ricevuto E; Vicentini C; Bologna M
Prostate; 2007 Sep; 67(12):1255-64. PubMed ID: 17596848
[TBL] [Abstract][Full Text] [Related]
15. Human prostatic tumor cells in culture produce growth and differentiation factors active on osteoblasts: a new biological and clinical parameter for prostatic carcinoma.
Festuccia C; Teti A; Bianco P; Guerra F; Vicentini C; Tennina R; Villanova I; Sciortino G; Bologna M
Oncol Res; 1997; 9(8):419-31. PubMed ID: 9436195
[TBL] [Abstract][Full Text] [Related]
16. Rational basis for Trk inhibition therapy for prostate cancer.
Weeraratna AT; Arnold JT; George DJ; DeMarzo A; Isaacs JT
Prostate; 2000 Oct; 45(2):140-8. PubMed ID: 11027413
[TBL] [Abstract][Full Text] [Related]
17. Novel titanocene anti-cancer drugs and their effect on apoptosis and the apoptotic pathway in prostate cancer cells.
O'Connor K; Gill C; Tacke M; Rehmann FJ; Strohfeldt K; Sweeney N; Fitzpatrick JM; Watson RW
Apoptosis; 2006 Jul; 11(7):1205-14. PubMed ID: 16699961
[TBL] [Abstract][Full Text] [Related]
18. Fibroblast growth factor-2 induces osteoblast survival through a phosphatidylinositol 3-kinase-dependent, -beta-catenin-independent signaling pathway.
Debiais F; Lefèvre G; Lemonnier J; Le Mée S; Lasmoles F; Mascarelli F; Marie PJ
Exp Cell Res; 2004 Jul; 297(1):235-46. PubMed ID: 15194439
[TBL] [Abstract][Full Text] [Related]
19. Role of NF-kappaB in hematopoietic niche function of osteoblasts after radiation injury.
Xiao M; Inal CE; Parekh VI; Li XH; Whitnall MH
Exp Hematol; 2009 Jan; 37(1):52-64. PubMed ID: 18954936
[TBL] [Abstract][Full Text] [Related]
20. The novel antimicrotubule agent cryptophycin 52 (LY355703) induces apoptosis via multiple pathways in human prostate cancer cells.
Drew L; Fine RL; Do TN; Douglas GP; Petrylak DP
Clin Cancer Res; 2002 Dec; 8(12):3922-32. PubMed ID: 12473608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
